What We're Reading: Page 138
Industry reads hand-picked by our editors
Sep 24, 2021
-
The Wall Street Journal
M&A Banker Found Promise in Nascent Biotechnology Companies
-
Kaiser Health News
Biosimilar Drugs Are Cheaper Than Biologics. Are They Similar Enough to Switch?
-
Reuters
Doctors scale rockslides, invoke gods to vaccinate Himalayan villages
Sep 23, 2021
-
POLITICO
Pfizer CEO rallies staff to fight Democrats' drug price negotiation
-
Bloomberg
Vaccinated Pregnant Women Pass Protection to Babies in Study
-
Financial Times
Activist Bluebell takes stake in GlaxoSmithKline to push for change at top
-
Evaluate Vantage
The heat is on Gilead as Tropics readout nears
Sep 22, 2021
-
STAT
Biogen considers cost-cutting measures after slow Aduhelm sales
-
The New York Times
Pressure Grows on U.S. Companies to Share Covid Vaccine Technology
-
Fierce Pharma
Amgen scores Otezla patent win, nabbing protection until 2028
-
NPR
The FDA Has Been Without A Permanent Leader For 8 Months, As COVID Cases Climb
Sep 21, 2021
Sep 20, 2021
Sep 17, 2021
-
Endpoints News
The biggest questions facing gene therapy, the XLMTM community, and Astellas after fourth patient death
-
Evaluate Vantage
Biogen leads the amyotrophic lateral sclerosis hopefuls
-
STAT
New study revives a Mozart sonata as a potential epilepsy therapy
-
Reuters
China's biotech sector comes of age with big licensing deals, global ambitions
Sep 16, 2021
-
The Washington Post
At the besieged FDA, ‘it never stops!’ as decisions loom on boosters, pediatric shots and more
-
Business Insider
How China quietly grew into a biotech powerhouse that will shape the future of the drug industry
-
The New York Times
Democrats’ Stumble on Drug Prices Shows Power of Industry
-
Kaiser Health News
How Fauci and the NIH Got Ahead of the FDA and CDC in Backing Boosters
Previous
